{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:07:19Z","timestamp":1761919639362},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2012]]},"DOI":"10.2169\/internalmedicine.51.7771","type":"journal-article","created":{"date-parts":[[2012,9,15]],"date-time":"2012-09-15T01:02:16Z","timestamp":1347670936000},"page":"2625-2629","source":"Crossref","is-referenced-by-count":14,"title":["New-Onset Type 1 Diabetes Mellitus and Anti-Aquaporin-4 Antibody Positive Optic Neuritis Associated with Type 1 Interferon Therapy for Chronic Hepatitis C"],"prefix":"10.2169","volume":"51","author":[{"given":"Tomoya","family":"Kawazoe","sequence":"first","affiliation":[{"name":"Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youwei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamamura","sequence":"additional","affiliation":[{"name":"Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Wakakura","sequence":"additional","affiliation":[{"name":"Inouye Eye Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Burdick LM, Somani N, Somani AK. Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 8: 459-472, 2009.","DOI":"10.1517\/14740330903066726"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 42: 2204-2212, 1999.","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 340: 548, 1992.","DOI":"10.1016\/0140-6736(92)91744-S"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25: 283-291, 1996.","DOI":"10.1016\/S0168-8278(96)80113-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Manesis EK, Petrou C, Brouzas D, Hadziyannis S. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 21: 474-477, 1994.","DOI":"10.1016\/S0168-8278(05)80331-9"},{"key":"6","unstructured":"6. Isler M, Akhan G, Bardak Y, Akkaya A. Dry cough and optic neuritis: two rare complications of interferon alpha treatment in chronic viral hepatitis. Am J Gastroenterol 96: 1303-1304, 2001."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Matsuo T, Takabatake R. Multiple sclerosis-like disease secondary to alpha interferon. Ocul Immunol Inflamm 10: 299-304, 2002.","DOI":"10.1076\/ocii.10.4.299.15588"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kataoka I, Shinagawa K, Shiro Y, et al. Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. Am J Hematol 70: 149-153, 2002.","DOI":"10.1002\/ajh.10090"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. H&ouml;ftberger R, Garzuly F, Dienes HP, et al. Fulminant central nervous system demyelination associated with interferon-alpha therapy and hepatitis C virus infection. Mult Scler 13: 1100-1106, 2007.","DOI":"10.1177\/1352458507078684"},{"key":"10","unstructured":"10. Kajiyama K, Tsuda K, Takeda M, Yoshikawa H, Tanaka K. Multiple sclerosis with positive anti-aquaporin-4 antibody, manifested after interferon-a-2b\/ribavirin therapy for chronic hepatitis C. A case report. Shinkeinaika (Neurol Med) 66: 180-184, 2007 (in Japanese, Abstract in English)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yamasaki M, Matsumoto K, Takahashi Y, Nakanishi H, Kawai Y, Miyamura M. A case of NMO (Neuromyelitis optica) spectrum disorder triggered by interferon alpha, which involved extensively pyramidal tract lesion of the brain. Rinshou Shinkeigaku (Clin Neurol) 52: 19-24, 2012.","DOI":"10.5692\/clinicalneurol.52.19"},{"key":"12","unstructured":"12. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Okuma H, Kawamura Y, Ohnuki Y, Takagi S. Optic neuritis caused by interferon-beta administration. Intern Med 47: 1759, 2008.","DOI":"10.2169\/internalmedicine.47.1401"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFN&beta;-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75: 1423-1427, 2010.","DOI":"10.1212\/WNL.0b013e3181f8832e"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489, 2006.","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130: 1206-1223, 2007.","DOI":"10.1093\/brain\/awm027"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tanaka M, Tanaka K, Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 62: 167-170, 2009.","DOI":"10.1159\/000227277"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 17: 672-676, 2010.","DOI":"10.1111\/j.1468-1331.2009.02897.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shimizu Y, Fujihara K, Kubo S, et al. Therapeutic efficacy of interferon b-1b in Japanese patients with optic-spinal multiple sclerosis. Tohoku J Exp Med 223: 211-214, 2011.","DOI":"10.1620\/tjem.223.211"},{"key":"20","unstructured":"20. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131: 1455-1463, 2008."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108: 3701-3706, 2011.","DOI":"10.1073\/pnas.1017385108"},{"key":"22","unstructured":"22. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224-1234, 2007."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Axtell RC, Raman C, Steinman L. Interferon-b exacerbates Th17-mediated inflammatory disease. Trends Immunol 32: 272-277, 2011.","DOI":"10.1016\/j.it.2011.03.008"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Crow MK. Type 1 interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 12 (Suppl 1): S5-S14, 2010.","DOI":"10.1186\/ar2886"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Knobler RL, Panitch HS, Braheny SL, et al. Systemic alpha-interferon therapy of multiple sclerosis. Neurology 34: 1273-1279, 1984.","DOI":"10.1212\/WNL.34.10.1273"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/18\/51_51.7771\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:44:45Z","timestamp":1621446285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/18\/51_51.7771\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":25,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.51.7771","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}